Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
HighlightsWith deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
HighlightsGet a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
HighlightsIn the intricate landscape of therapeutic drug development, particularly for monoclonal antibodies, antibody-drug conjugates (ADCs), and cell therapies like CAR-T, the precise and accurate characterization of your drug candidate is paramount. Anti-idiotypic antibodies (anti-ID Abs) are indispensable tools in this process, serving as critical reagents for pharmacokinetic (PK), immunogenicity (anti-drug antibody, ADA), and neutralizing antibody (NAB) assays. With over two decades of dedicated expertise, Creative Biolabs stands at the forefront of immunological services. We have honed our Rabbit Anti-Idiotypic Antibody Discovery Service to an unparalleled level of sophistication. By harnessing the robust immune system of rabbits, we deliver anti-ID antibodies with superior affinity, diversity, and specificity, providing you with the reliable tools essential for advancing your drug program from preclinical discovery to potential clinical success.
While rodents like mice are commonly used, rabbits present a distinct and often superior immunological advantage for generating high-quality anti-idiotypic antibodies. The unique physiology of the rabbit immune system translates directly into better reagents for your assays.
| Feature | Murine (Mouse) System | Rabbit System (Creative Biolabs' Choice) |
| Antibody Affinity | Good (Nanomolar range) | Excellent (Picomolar range) |
| Epitope Diversity | Moderate | Exceptional |
| Sensitivity in Assays | Standard | High to Very High |
| Success Rate for Difficult Targets | Moderate | High |
| Ideal For | Standard immunogenicity studies | Highly sensitive PK assays, NAB assays, and challenging drug targets |
At Creative Biolabs, we don't believe in a one-size-fits-all approach. We tailor our discovery strategy to your specific drug molecule, timeline, and downstream application. We offer a suite of cutting-edge platforms to ensure optimal outcomes.
A classic and robust method, our optimized hybridoma platform is perfect for generating high-quality monoclonal anti-ID antibodies. We have refined every step, from proprietary immunization strategies to high-throughput screening, to ensure the generation of stable, high-yield hybridoma cell lines producing antibodies with desired characteristics.
For unparalleled speed and the ability to discover antibodies against challenging or toxic drug targets, our phage display platform is the ideal choice. We can construct custom immune libraries from immunized rabbits and rapidly screen billions of antibody candidates to isolate rare binders with exquisite specificity and affinity, including those that are difficult to obtain through traditional methods.
This is our most advanced platform, representing the pinnacle of antibody discovery technology. The Native™ single B cell sorting platform allows for the direct isolation and sequencing of antigen-specific B cells from immunized rabbits. This approach captures the naturally selected, in vivo-matured antibody repertoire, leading to the rapid discovery of native heavy-and-light-chain-paired antibodies with superior affinity and developability profiles.
| Platform | Key Advantage | Typical Timeline | Best For |
| Advanced Hybridoma | Robust, stable cell lines, proven technology. | 16-20 Weeks | Standard PK and ADA assay development. |
| Phage Display | High throughput, fast screening, non-animal screening. | 10-14 Weeks | Difficult/toxic antigens, specific epitope targeting. |
| Native™ Single B-Cell | Fastest, native pairing, highest affinity, captures natural diversity. | 6-10 Weeks | Urgent projects, challenging targets, superior affinity requirements. |
We believe in a transparent, milestone-driven process that keeps you in control.
Phase 1: Project Consultation and Strategy Design
Our Ph.D.-level scientists consult with you to understand your drug molecule, project goals, and required antibody specifications. We then design a bespoke discovery strategy.
Phase 2: Rabbit Immunization & Immune Response Monitoring
We employ proprietary adjuvant and immunization protocols to elicit a potent and diverse anti-idiotypic response in rabbits. Serum titers are meticulously monitored via ELISA.
Phase 3: High-Throughput Discovery and Screening
Utilizing the chosen platform (Hybridoma, Phage Display, or Single B-Cell), we generate and screen a vast number of antibody candidates to identify positive hits.
Phase 4: Recombinant Antibody Production and Purification
Positive candidates are expressed as recombinant antibodies and purified to the highest standards, ensuring consistency and purity for your assays.
Phase 5: In-depth Characterization
We perform a full suite of characterization assays, including affinity measurement (via SPR/BLI), specificity testing, epitope binning, and functional validation (blocking/non-blocking/complex-specific).
Phase 6: Final Deliverables and Comprehensive Report
You receive your high-quality rabbit anti-idiotypic antibodies, along with a detailed report including all data, protocols, and characterization results.
Understanding the type of anti-ID antibody required is crucial for successful assay development. We specialize in discovering and characterizing all major functional types to meet diverse project needs.
Fig. 1 Anti-Idiotypic Antibodies.
Mechanism: These antibodies bind to the paratope (the antigen-binding site) of your drug antibody and directly compete with the target antigen.
Primary Application: Ideal as a reference standard in neutralizing antibody (NAB) assays and for PK assays that use a competitive ELISA format.
Mechanism: Binds to an idiotope outside the paratope of your drug antibody. It can bind the drug antibody whether or not the antigen is bound.
Primary Application: Commonly used as the capture or detection reagent in bridging ELISA formats for both PK and ADA assays.
Mechanism: This sophisticated type of antibody only recognizes the drug antibody when it is bound to its target antigen. It binds to a neo-epitope formed by the complex.
Primary Application: Used to measure the level of the drug that is actively engaged with its target in vivo, providing critical insights for pharmacodynamic (PD) studies.
Choosing a service provider is a critical decision. Here’s why leading pharmaceutical and biotech companies trust Creative Biolabs:
Other optional anti-idiotypic antibody discovery services:
Propel your therapeutic drug program forward with rabbit anti-idiotypic antibodies of the highest caliber. Contact our team of experts today to discuss your project and receive a customized, no-obligation proposal.
Q: What material do I need to provide?
A: Typically, we require 1-5 mg of your therapeutic antibody drug. We will provide a detailed project-specific list upon consultation.
Q: What is the typical timeline for rabbit anti-ID monoclonal antibody discovery?
A: The timeline depends on the platform. Our cutting-edge Single B-Cell platform can deliver final antibodies in as little as 6-10 weeks, while hybridoma projects are typically 16-20 weeks.
Q: Can you generate anti-ID antibodies against complex formats like bispecifics or ADCs?
A: Absolutely. Our platforms are well-suited for complex biologics. We have extensive experience developing anti-ID antibodies specific to the unique domains or conjugations of these molecules.
Q: What level of characterization is included?
A: Our standard package includes comprehensive characterization: affinity measurement (KD), ELISA titration, and functional classification (e.g., blocking vs. non-blocking). Additional characterization services are available upon request.
All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.
